{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:38:47Z","timestamp":1792431527157,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.critrevonc.2017.04.011","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T16:31:43Z","timestamp":1493310703000},"page":"50-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy"],"prefix":"10.1016","volume":"115","author":[{"given":"Nabil F.","family":"Saba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur D.","family":"Mody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpaul S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Rinaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Takes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Primo\u017e","family":"Strojan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana M.","family":"Hartl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan B.","family":"Vermorken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Missak","family":"Haigentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfio","family":"Ferlito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.critrevonc.2017.04.011_bib0005","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/14712598.2016.1211635","article-title":"Pembrolizumab: the value of PDL1 biomarker in head and neck cancer","volume":"16","author":"Addeo","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.04.011_bib0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.04.011_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.oraloncology.2015.11.019","article-title":"Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: a literature review","volume":"53","author":"Ahn","year":"2016","journal-title":"Oral Oncol."},{"issue":"June (3)","key":"10.1016\/j.critrevonc.2017.04.011_bib0020","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00001813-199506000-00003","article-title":"Cisplatin-associated neurotoxicity: can it be prevented?","volume":"6","author":"Alberts","year":"1995","journal-title":"Anticancer Drugs"},{"issue":"September (9)","key":"10.1016\/j.critrevonc.2017.04.011_bib0025","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.oraloncology.2014.06.014","article-title":"Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck","volume":"50","author":"Behera","year":"2014","journal-title":"Oral Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2017.04.011_bib0030","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer","volume":"350","author":"Bernier","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"December (4)","key":"10.1016\/j.critrevonc.2017.04.011_bib0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/jmrs.132","article-title":"The provision of enteral nutritional support during definitive chemoradiotherapy in head and neck cancer patients","volume":"62","author":"Bishop","year":"2015","journal-title":"J. Med. Radiat. Sci."},{"issue":"23","key":"10.1016\/j.critrevonc.2017.04.011_bib0040","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1200\/JCO.2012.47.7802","article-title":"Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group","volume":"31","author":"Blanchard","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2017.04.011_bib0045","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2165\/00003495-200767170-00008","article-title":"Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer","volume":"67","author":"Blick","year":"2007","journal-title":"Drugs"},{"issue":"February (6)","key":"10.1016\/j.critrevonc.2017.04.011_bib0050","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2017.04.011_bib0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol."},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2017.04.011_bib0060","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/hed.23170","article-title":"afety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer","volume":"35","author":"Bossi","year":"2013","journal-title":"Head Neck"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.04.011_bib0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.radonc.2015.10.014","article-title":"Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): a meta-analysis of randomized trials","volume":"118","author":"Budach","year":"2016","journal-title":"Radiother. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2017.04.011_bib0070","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1634\/theoncologist.2009-0090","article-title":"Radiation recall with anticancer agents","volume":"15","author":"Burris","year":"2010","journal-title":"Oncologist"},{"issue":"December (34)","key":"10.1016\/j.critrevonc.2017.04.011_bib0075","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","article-title":"Eastern Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study","volume":"23","author":"Burtness","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"October (5)","key":"10.1016\/j.critrevonc.2017.04.011_bib0080","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10637-008-9128-1","article-title":"Favorable survival observedafter carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma","volume":"26","author":"Carter","year":"2008","journal-title":"Invest. New Drugs"},{"issue":"June (6)","key":"10.1016\/j.critrevonc.2017.04.011_bib0085","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1726-4901(10)70064-2","article-title":"Cetuximab-based therapy in recurrent\/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular","volume":"73","author":"Chang","year":"2010","journal-title":"J. Chin. Med. Assoc."},{"issue":"May (5)","key":"10.1016\/j.critrevonc.2017.04.011_bib0090","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/cam4.408","article-title":"Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III and IV squamous cell carcinoma of the oropharynx. A GERCOR phase IIECHO-07 study","volume":"4","author":"Chibaudal","year":"2015","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2017.04.011_bib0095","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort","author":"Chow","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"August (8)","key":"10.1016\/j.critrevonc.2017.04.011_bib0100","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/annonc\/mdw151","article-title":"Afatinib versus methotrexate in older patients with second-line recurrent and\/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial","volume":"27","author":"Clement","year":"2016","journal-title":"Ann. Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2017.04.011_bib0105","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.2013.54.6309","article-title":"Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer","volume":"32","author":"Cohen","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2017.04.011_bib0110","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck","volume":"350","author":"Cooper","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"March-April (2)","key":"10.1016\/j.critrevonc.2017.04.011_bib0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/PPO.0000000000000186","article-title":"Managing adverse events with immune checkpoint agents","volume":"22","author":"Dadu","year":"2016","journal-title":"Cancer J."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.04.011_bib0120","first-page":"527","article-title":"Audiological findings in patients treated with radiotherapy for head and neck tumors","volume":"76","author":"Dell\u2019aringa","year":"2010","journal-title":"Braz. J. Otorhinolaryngol."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.04.011_bib0125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2004.08.021","article-title":"Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma","volume":"22","author":"Denis","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.04.011_bib0130","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00281-016-0595-8","article-title":"Cancer immunotherapy in patients with preexisting autoimmune disorders","volume":"39","author":"Donia","year":"2016","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.critrevonc.2017.04.011_bib0135","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00204-012-0821-7","article-title":"Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update","volume":"86","author":"dos Santos","year":"2012","journal-title":"Arch. Toxicol."},{"issue":"September (14)","key":"10.1016\/j.critrevonc.2017.04.011_bib0140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tox.2016.10.001","article-title":"An integrative view of cisplatin-induced renal and cardiac toxicities: molecular mechanisms, current treatment challenges and potential protective measures","volume":"371","author":"Dugbartey","year":"2016","journal-title":"Toxicology"},{"key":"10.1016\/j.critrevonc.2017.04.011_bib0145","first-page":"196","article-title":"Incidence and risk factors of hypomagnesmia in head and neck cancer patients treated with cetuximab","volume":"6","author":"Enokida Suzuki","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2017.04.011_bib0150","doi-asserted-by":"crossref","DOI":"10.1097\/COC.0000000000000301","article-title":"Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy","author":"Faig","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"issue":"November (19)","key":"10.1016\/j.critrevonc.2017.04.011_bib0155","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Eng. J. Med."},{"issue":"October (15)","key":"10.1016\/j.critrevonc.2017.04.011_bib0160","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2165\/11205010-000000000-00000","article-title":"Cetuximab: a review of its use in squamous cell carcinoma of the head and neck","volume":"70","author":"Frampton","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2017.04.011_bib0165","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/106002809202600219","article-title":"Methotrexate and nonsteroidal antiinflammatory drug interactions","volume":"26","author":"Frenia","year":"1992","journal-title":"Ann. Pharmacother."},{"issue":"November (11)","key":"10.1016\/j.critrevonc.2017.04.011_bib0170","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1080\/14740338.2016.1227789","article-title":"Safety of drug treatments for head and neck cancer","volume":"15","author":"Galot","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2017.04.011_bib0175","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.oraloncology.2014.12.011","article-title":"A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"51","author":"Gilbert","year":"2015","journal-title":"Oral Oncol."},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2017.04.011_bib0180","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2008.09.007","article-title":"High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes","volume":"90","author":"Giro","year":"2009","journal-title":"Radiother. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.04.011_bib0185","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/CAD.0000000000000055","article-title":"Taxanes as radiosensitizers","volume":"25","author":"Golden","year":"2014","journal-title":"Anticancer Drugs"},{"issue":"Suppl. May (5)","key":"10.1016\/j.critrevonc.2017.04.011_bib0190","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/annonc\/mdq185","article-title":"Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment, and follow-up","volume":"21","author":"Gregoire","year":"2010","journal-title":"Ann. Oncol."},{"issue":"February (6)","key":"10.1016\/j.critrevonc.2017.04.011_bib0195","doi-asserted-by":"crossref","first-page":"7110","DOI":"10.18632\/oncotarget.6858","article-title":"A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN)","volume":"7","author":"Guan","year":"2016","journal-title":"Oncotarget"},{"issue":"September (9)","key":"10.1016\/j.critrevonc.2017.04.011_bib0200","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/annonc\/mdv268","article-title":"Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study","volume":"26","author":"Guigay","year":"2015","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2017.04.011_bib0205","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1002\/cncr.24525","article-title":"Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin\/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer","volume":"115","author":"Haddad","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2017.04.011_bib0210","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial","volume":"14","author":"Haddad","year":"2013","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.04.011_bib0215","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/annonc\/mdt461","article-title":"A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherpy alone as treatment of unresectable head and neck cancer","volume":"25","author":"Hitt","year":"2014","journal-title":"Ann. Oncol."},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2017.04.011_bib0220","article-title":"Nephrotoxicity as a dose-limiting factor in a high-dose cisplatin-based chemoradiotherapy regimen for head and neck carcinomas","volume":"8","author":"Hoek","year":"2016","journal-title":"Cancers (Basel)"},{"issue":"August (8)","key":"10.1016\/j.critrevonc.2017.04.011_bib0225","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1349-7006.2007.00510.x","article-title":"Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor","volume":"98","author":"Kimura","year":"2007","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.04.011_bib0230","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"April (10)","key":"10.1016\/j.critrevonc.2017.04.011_bib0235","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","article-title":"Peripheral neuropathy induced by microtubule-stabilizing agents","volume":"24","author":"Lee","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2017.04.011_bib0240","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.ejca.2012.12.009","article-title":"Targeted therapy-induced radiation recall","volume":"49","author":"Levy","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.04.011_bib0245","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.oraloncology.2014.12.005","article-title":"Immunotherapy for head and neck squamous cell carcinoma","volume":"51","author":"Li","year":"2015","journal-title":"Oral Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.04.011_bib0250","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"May (5)","key":"10.1016\/j.critrevonc.2017.04.011_bib0255","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1517\/17425255.2015.1027684","article-title":"Pharmacogenomics of fluorouracil-based chemotherapy toxicity","volume":"11","author":"Matsusaka","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"December (12)","key":"10.1016\/j.critrevonc.2017.04.011_bib0260","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.oraloncology.2014.08.009","article-title":"Pre-medications for cetuximab induced infusion reactions \u2212commentary","volume":"50","author":"McKibbin","year":"2014","journal-title":"Oral Oncol."},{"issue":"April (4)","key":"10.1016\/j.critrevonc.2017.04.011_bib0265","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00520-015-2978-0","article-title":"Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy","volume":"24","author":"McKibbin","year":"2016","journal-title":"Support Care Cancer"},{"issue":"4684","key":"10.1016\/j.critrevonc.2017.04.011_bib0270","article-title":"Head and neck cancer-Part 1: epidemiology, presentation, and prevention","volume":"341","author":"Mehanna","year":"2010","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.critrevonc.2017.04.011_bib0275","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1517\/14656566.3.6.755","article-title":"Paclitaxel in cancer therapy","volume":"3","author":"Mekhail","year":"2002","journal-title":"Expert Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.04.011_bib0280","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD \u22121 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2016","journal-title":"Ann. Oncol."},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2017.04.011_bib0285","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijrobp.2015.10.019","article-title":"A phase 2 open label, single-arm trial to evaluate the combination of cetuximab plus taxotere, cisplatin, and 5-flurouracil as an induction regimen in patients with unresectable squamous cell carcinoma of the head and neck","volume":"94","author":"Mesia","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"February","key":"10.1016\/j.critrevonc.2017.04.011_bib0290","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"September (9)","key":"10.1016\/j.critrevonc.2017.04.011_bib0295","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/jamaoto.2016.1238","article-title":"The evolving and future role of taxanes in squamous cell carcinomas of the head and neck: a review","volume":"142","author":"Mody","year":"2016","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2017.04.011_bib0300","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00432-014-1801-5","article-title":"Severe gastrointestinal bleeding in patients with locally advanced head and neck squamous cell carcinoma treated by concurrent radiotherapy and cetuximab","volume":"141","author":"Murakami","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.04.011_bib0305","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.7314\/APJCP.2016.17.4.1617","article-title":"Three weekly versus weekly cisplatin as radiosensitizer in head and neck cancer: a decision dilemma","volume":"17","author":"Negi","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.04.011_bib0310","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother. Oncol."},{"issue":"April (7)","key":"10.1016\/j.critrevonc.2017.04.011_bib0315","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jnci\/djp007","article-title":"Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation","volume":"101","author":"Pointreau","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"17","key":"10.1016\/j.critrevonc.2017.04.011_bib0320","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"May (1)","key":"10.1016\/j.critrevonc.2017.04.011_bib0325","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s40064-015-0988-5","article-title":"Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety","volume":"4","author":"Qian","year":"2015","journal-title":"Springerplus"},{"issue":"July-August (108)","key":"10.1016\/j.critrevonc.2017.04.011_bib0330","first-page":"57","article-title":"Cisplatin based chemoradiation late toxicities in head and neck squamous cell carcinoma patients","volume":"20","author":"Rivelli","year":"2015","journal-title":"Discov. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.04.011_bib0335","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00520-016-3426-5","article-title":"Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity","volume":"25","author":"Saito","year":"2016","journal-title":"Support. Care Cancer"},{"issue":"August (7)","key":"10.1016\/j.critrevonc.2017.04.011_bib0340","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3109\/00016489.2015.1030772","article-title":"Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemotherapy for head and neck squamous cell carcinomas: a single-institution retrospective study in Japan","volume":"135","author":"Sakashita","year":"2015","journal-title":"Acta Otolaryngol."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.04.011_bib0345","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1517\/14656566.2016.1122757","article-title":"Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy","volume":"17","author":"Santabarbara","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"issue":"10","key":"10.1016\/j.critrevonc.2017.04.011_bib0350","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3109\/00016489.2015.1060631","article-title":"Factors predicting severe infections during chemotherapy in head and neck cancer patients","volume":"135","author":"Sasaki","year":"2015","journal-title":"Acta Otolaryngol."},{"key":"10.1016\/j.critrevonc.2017.04.011_bib0355","series-title":"Harrison\u2019s Principles of Internal Medicine","article-title":"Chapter 85. principles of cancer treatment","author":"Sausville","year":"2012"},{"issue":"July (7)","key":"10.1016\/j.critrevonc.2017.04.011_bib0360","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open label, multicenter, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.04.011_bib0365","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2008.17.0530","article-title":"Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck","volume":"27","author":"Stewart","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.04.011_bib0370","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/hed.23506","article-title":"TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck","volume":"36","author":"Strojan","year":"2014","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.critrevonc.2017.04.011_bib0375","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0360-3016(00)00408-9","article-title":"The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck","volume":"47","author":"Suntharalingam","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"December (12)","key":"10.1016\/j.critrevonc.2017.04.011_bib0380","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/lary.24802","article-title":"Long-term hearing loss after chemoradiation in patients with head and neck cancer","volume":"124","author":"Theunissen","year":"2014","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.04.011_bib0385","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hed.23551","article-title":"Sensorineural hearing loss in patients with head and neck cancer after chemotherapy and radiotherapy: a systemic review of the literature","volume":"37","author":"Theunissen","year":"2015","journal-title":"Head Neck"},{"issue":"February (4)","key":"10.1016\/j.critrevonc.2017.04.011_bib0390","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/ijc.30501","article-title":"Safety and efficacy of nivolumab in the treatment of cancers: a meta-analysis of 27 prospective clinical trials","volume":"140","author":"Tie","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2017.04.011_bib0395","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.radonc.2011.06.025","article-title":"Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent","volume":"100","author":"Tortochaux","year":"2011","journal-title":"Radiother. Oncol."},{"issue":"February (1)","key":"10.1016\/j.critrevonc.2017.04.011_bib0400","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11547-011-0716-3","article-title":"Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy","volume":"117","author":"Valeriani","year":"2012","journal-title":"Radiol. Med."},{"issue":"17","key":"10.1016\/j.critrevonc.2017.04.011_bib0405","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"June (1)","key":"10.1016\/j.critrevonc.2017.04.011_bib0410","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"16","author":"Vermorken","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2017.04.011_bib0415","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N. Eng. J. Med."},{"issue":"January (3)","key":"10.1016\/j.critrevonc.2017.04.011_bib0420","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1056\/NEJM199301213280306","article-title":"Head and neck cancer","volume":"328","author":"Vokes","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"January (1)","key":"10.1016\/j.critrevonc.2017.04.011_bib0425","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.radonc.2010.11.009","article-title":"Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC)","volume":"98","author":"Walsh","year":"2011","journal-title":"Radiother. Oncol."},{"issue":"June (8)","key":"10.1016\/j.critrevonc.2017.04.011_bib0430","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"October-December (4)","key":"10.1016\/j.critrevonc.2017.04.011_bib0435","first-page":"607","article-title":"Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab","volume":"9","author":"Ye","year":"2013","journal-title":"J. Cancer Res. Ther."},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2017.04.011_bib0440","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/jjco\/hyu196","article-title":"Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer","volume":"45","author":"Yokota","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"June (4)","key":"10.1016\/j.critrevonc.2017.04.011_bib0445","doi-asserted-by":"crossref","first-page":"10798","DOI":"10.1038\/srep10798","article-title":"Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817300306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817300306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T20:29:01Z","timestamp":1719174541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842817300306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":89,"alternative-id":["S1040842817300306"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.04.011","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}